Millipore Corporation v. Wl Gore & Associates, Inc.

750 F. Supp. 2d 253, 2010 U.S. Dist. LEXIS 99704, 2010 WL 3733997
CourtDistrict Court, D. Massachusetts
DecidedSeptember 20, 2010
DocketCivil Action 09-10765-DPW
StatusPublished
Cited by1 cases

This text of 750 F. Supp. 2d 253 (Millipore Corporation v. Wl Gore & Associates, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Millipore Corporation v. Wl Gore & Associates, Inc., 750 F. Supp. 2d 253, 2010 U.S. Dist. LEXIS 99704, 2010 WL 3733997 (D. Mass. 2010).

Opinion

MEMORANDUM AND ORDER

DOUGLAS P. WOODLOCK, District Judge.

Plaintiff Millipore Corporation (“Millipore”) brought this action against Defendant W.L. Gore & Associates, Inc. (“Gore”) for infringement of U.S. Patent No. 7,293,-477 (the “'477 Patent”). The '477 Patent relates to fluid sampling devices and kits comprising sterilized components of fluid sampling devices. In response, Gore has filed counterclaims for declaration of non-infringement, invalidity, and inequitable conduct, and has moved for summary judgment of non-infringement.

Under Federal Circuit law, “[ejvaluation of summary judgment of non-infringement requires two steps-proper claim construction and comparison of those claims to the accused product.” Trading Techs. Int’l, Inc. v. eSpeed, Inc., 595 F.3d 1340, 1350 (Fed.Cir.2010). Both steps are presented by the motion for summary judgment now before me. After addressing the background of the case and the relevant legal principles, I will construe the disputed claim terms and will compare the claims at issue to the accused products.

I. BACKGROUND

A. Technical Background

It is common practice in many industries to have manufacturing processes occur in fluid receptacles. For instance, pharmaceutical products are produced in chemical reactors and milk is pasteurized in pasteurization vats. To ensure the quality of the final product, these processes are customarily monitored by withdrawing fluid samples from time to time. Generally, it is important to keep the fluid samples unaltered, thereby requiring the withdrawal of sample fluid in a sterile manner. A sterile environment means being free from any contaminants that may affect the manufacturing process or the integrity of the sample, including bacteria, fungi, and viruses.

In order to withdraw samples from fluid receptacles, industries have used devices that were integrated with fluid receptacles. Integrated devices required laborious steam sterilization and cleaning which caused risk of sterility failure as well as significant equipment downtime. Other prior fluid sampling devices required the installation of custom fitted ports onto fluid receptacles. Customization of fluid receptacles resulted in additional costs. In light of these disadvantages, “a need exist[ed] for a fluid sampling device that [wa]s sufficiently inexpensive in its construction to promote single-use disposability, capable of being used in standard industrial ports commonly found in fluid receptacles, and capable of several good sterile fluid sample withdrawals per sterilization cycle and/or prior to being exhausted.” '477 Patent col. 1 11. 61-67.

B. '477 Patent

On November 13, 2007, the United States Patent and Trademark Office (“PTO”) issued the '477 Patent to Millipore. The '477 Patent is entitled “Disposable, Pre-Sterilized Fluid Receptacle Sampling Device” and consists of Claims 1 to 5, where Claims 1 and 5 are independent and *258 Claims 2, 3 and 4 are dependant. '477 Patent col. 8 1. 37 — col. 10 1.19.

As expressed in the specification, the '477 Patent “provides a fluid sampling device comprising a port insert, a plurality of flexible conduits, and a plurality of sample containers.” Id. at col. 2 11. 3-5. The purpose of the '477 Patent is to provide “a fluid sampling device that enables the withdrawal of several samples of fluids from a fluid receptacle, wherein said withdrawal occurs in a substantially sterile manner, and wherein inter-sample cross-contamination is substantially discouraged.” Id. at col. 2 11. 40-45. Users of the '477 Patent can withdraw one or more sterile fluid samples sequentially or simultaneously. Thereafter, the devices of the '477 Patent can be easily removed and replaced with a new sampling unit. The devices of the '477 Patent are designed to be simple in construction, inexpensive to manufacture, usable with standard industrial tanks or vats, and disposable after use, thereby eliminating the need for cleaning and resterilization.

C. Gore’s Accused Products

Millipore contends that Gore infringes the '477 Patent by making, selling, and importing its Five-Valve STA-PURE™ Fluid Sampling System and Single-Valve STA-PURE" Fluid Sampling System (collectively, the “Accused Products”). Specifically, Millipore contends that the Five-Valve Sampler infringes Claims 1 to 5 and that the Single-Valve Sampler infringes Claim 5, both of these infringements are said to be literal as well as under the doctrine of equivalents. The Five-Valve Sampler and the Single-Valve Sampler use a similar valve structure, which is the focus of Millipore’s patent infringement allegations.

D. Procedural History

Millipore commenced this action on May 11, 2009 against Gore alleging infringement of the '477 Patent (Count I). Gore counterclaimed on August 5, 2009 seeking declaratory judgment of non-infringement and invalidity of the '477 Patent.

On January 20, 2010, Gore filed an Opening Claim Construction Brief disputing a total of nine claim terms contained in Claims 1 and 5 of the '477 Patent. Simultaneously, Gore filed a motion for summary judgment of non-infringement based on its proposed construction of the cap-related limitations recited in the asserted claims. For its part, Millipore filed an Opening Claim Construction Brief disputing seventeen claim terms used in Claims 1 to 5 of the '477 Patent.

On May 19, 2010, I had a hearing to discuss claim construction and address the pending motions. During the hearing, I indicated my initial inclinations on claim construction while reserving the right to refine them after taking the claim construction under advisement. I set a further hearing regarding Gore’s motion for summary judgment for September 8, 2010. This memorandum will definitively resolve the outstanding claim construction questions and the pending summary judgment motion.

II. CLAIM CONSTRUCTION

At issue are disputed claim terms from Claims 1 to 5 of the '477 Patent. 1 I must *259 construe the disputed claim terms according to the settled principles of claim construction.

A. Legal Considerations

Under Federal Circuit law, it is a “bedrock principle” that “the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed.Cir.2005) (en banc) (quoting Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1115 (Fed.Cir.2004)). “[T]he construction of a patent, including terms of art within its claim, is exclusively within the province of the court.” Markman v. Westview Instruments, Inc., 517 U.S. 370, 372, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996).

Claim terms are “generally given their ordinary and customary meaning.” Phillips, 415 F.3d at 1312 (quoting Vitronics Corp. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Davis Innovations, Inc. v. SIG Sauer, Inc., et al.
2017 DNH 028 (D. New Hampshire, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
750 F. Supp. 2d 253, 2010 U.S. Dist. LEXIS 99704, 2010 WL 3733997, Counsel Stack Legal Research, https://law.counselstack.com/opinion/millipore-corporation-v-wl-gore-associates-inc-mad-2010.